Kamada Ltd (NASDAQ:KMDA) – Stock analysts at Jefferies Group issued their Q1 2018 earnings per share (EPS) estimates for Kamada in a report released on Thursday. Jefferies Group analyst R. Denhoy expects that the biotechnology company will post earnings of $0.02 per share for the quarter. Jefferies Group also issued estimates for Kamada’s Q2 2018 earnings at $0.06 EPS, FY2018 earnings at $0.23 EPS, FY2019 earnings at $0.42 EPS, FY2020 earnings at $0.62 EPS and FY2021 earnings at $0.38 EPS.
Kamada (NASDAQ:KMDA) last issued its earnings results on Wednesday, February 7th. The biotechnology company reported $0.16 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.10. The business had revenue of $35.71 million during the quarter, compared to analysts’ expectations of $32.90 million. Kamada had a return on equity of 9.06% and a net margin of 6.71%.
Several other analysts have also recently commented on KMDA. TheStreet raised Kamada from a “c” rating to a “b” rating in a research report on Friday, February 9th. Zacks Investment Research raised Kamada from a “sell” rating to a “hold” rating in a research report on Friday, February 9th. ValuEngine raised Kamada from a “sell” rating to a “hold” rating in a research report on Thursday, February 8th. HC Wainwright reaffirmed a “buy” rating on shares of Kamada in a research report on Thursday, February 8th. Finally, Chardan Capital assumed coverage on Kamada in a research report on Friday, February 2nd. They issued a “buy” rating and a $7.00 target price for the company. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Kamada presently has an average rating of “Buy” and an average target price of $7.00.
Shares of Kamada (KMDA) opened at $5.25 on Monday. The company has a market capitalization of $207.35, a price-to-earnings ratio of 30.29 and a beta of 1.14. The company has a quick ratio of 2.58, a current ratio of 3.30 and a debt-to-equity ratio of 0.02. Kamada has a 12-month low of $3.75 and a 12-month high of $8.61.
Several large investors have recently made changes to their positions in the stock. ARK Investment Management LLC purchased a new stake in shares of Kamada during the fourth quarter worth $251,000. Jane Street Group LLC purchased a new stake in shares of Kamada during the third quarter worth $112,000. Analyst IMS Investment Management Services Ltd. raised its holdings in shares of Kamada by 125.5% during the third quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock worth $431,000 after acquiring an additional 50,000 shares in the last quarter. Worth Venture Partners LLC purchased a new stake in shares of Kamada during the third quarter worth $246,000. Finally, Paulson & CO. Inc. raised its holdings in shares of Kamada by 8.2% during the second quarter. Paulson & CO. Inc. now owns 790,800 shares of the biotechnology company’s stock worth $4,745,000 after acquiring an additional 60,000 shares in the last quarter. Institutional investors and hedge funds own 6.26% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/14/jefferies-group-comments-on-kamada-ltds-q1-2018-earnings-kmda.html.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.